Cargando…

Antidepressant-like properties of sarizotan in experimental Parkinsonism

RATIONALE: Depression and anxiety are common symptoms in Parkinson's disease for which there are no optimal treatments. Sarizotan, an agonist at serotonin receptors and partial agonist at dopamine D(2)-like receptors, has shown antidyskinetic effects in Parkinson's disease. Based on its ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiaoqun, Egeland, Martin, Svenningsson, Per
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222806/ https://www.ncbi.nlm.nih.gov/pubmed/21647579 http://dx.doi.org/10.1007/s00213-011-2356-7

Ejemplares similares

Potent hERG channel inhibition by sarizotan, an investigative treatment for Rett Syndrome
por: Cheng, Hongwei, et al.
Publicado: (2019)

Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
por: Schintu, Nicoletta, et al.
Publicado: (2020)

Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism
por: Monnot, Cyril, et al.
Publicado: (2017)

Intramolecular carbolithiation of N-allyl-ynamides: an efficient entry to 1,4-dihydropyridines and pyridines – application to a formal synthesis of sarizotan
por: Gati, Wafa, et al.
Publicado: (2012)

Antidepressants normalize elevated Toll-like receptor profile in major depressive disorder
por: Hung, Yi-Yung, et al.
Publicado: (2015)

No benefit of antidepressants in inpatient treatment of depression. A longitudinal, quasi-experimental field study
por: Maß, Reinhard, et al.
Publicado: (2023)

Antidepressant-like activity of magnesium in the olfactory bulbectomy model is associated with the AMPA/BDNF pathway
por: Pochwat, Bartlomiej, et al.
Publicado: (2014)

No antidepressant-like acute effects of bright light on emotional information processing in healthy volunteers
por: Kaltenboeck, Alexander, et al.
Publicado: (2021)

Prosaposin maintains lipid homeostasis in dopamine neurons and counteracts experimental parkinsonism in rodents
por: He, Yachao, et al.
Publicado: (2023)

Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation
por: Ma, Min, et al.
Publicado: (2016)

On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039
por: Pałucha-Poniewiera, Agnieszka, et al.
Publicado: (2010)

Deficits in Motor Performance, Neurotransmitters and Synaptic Plasticity in Elderly and Experimental Parkinsonian Mice Lacking GPR37
por: Zhang, Xiaoqun, et al.
Publicado: (2020)

Synergistic antidepressant- and anxiolytic-like effects of harmaline along with cinanserin in acute restraint stress-treated mice
por: Mosaffa, Sajedeh, et al.
Publicado: (2020)

Withdrawal of caffeine after its chronic administration modifies the antidepressant-like activity of atypical antidepressants in mice. Changes in cortical expression of Comt, Slc6a15 and Adora1 genes
por: Szopa, Aleksandra, et al.
Publicado: (2018)

Update on GPCR-based targets for the development of novel antidepressants
por: Mantas, Ioannis, et al.
Publicado: (2021)

Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson’s disease
por: Kamińska, Kinga, et al.
Publicado: (2022)

Trace Amine-Associated Receptor 1 Contributes to Diverse Functional Actions of O-Phenyl-Iodotyramine in Mice but Not to the Effects of Monoamine-Based Antidepressants
por: Mantas, Ioannis, et al.
Publicado: (2021)

Antidepressant-like activity of the neuropeptide Y Y5 receptor antagonist Lu AA33810: behavioral, molecular, and immunohistochemical evidence
por: Domin, Helena, et al.
Publicado: (2016)

Antidepressants and lethal violence in the Netherlands 1994–2008
por: Bouvy, Paul F., et al.
Publicado: (2012)

The selective 5-HT(1A) receptor biased agonists, F15599 and F13714, show antidepressant-like properties after a single administration in the mouse model of unpredictable chronic mild stress
por: Głuch-Lutwin, Monika, et al.
Publicado: (2021)

Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats
por: Podkowa, Karolina, et al.
Publicado: (2016)

Retroinverso analogs of spadin display increased antidepressant effects
por: Veyssiere, Julie, et al.
Publicado: (2014)

Decreased suicide rates in recent antidepressant clinical trials
por: Khan, Arif, et al.
Publicado: (2018)

Antidepressant Use and Mortality Among Patients With Hepatocellular Carcinoma
por: Huang, Kuan-Lun, et al.
Publicado: (2023)

Exploring the role of drug-metabolising enzymes in antidepressant side effects
por: Hodgson, Karen, et al.
Publicado: (2015)

Association of Linezolid With Risk of Serotonin Syndrome in Patients Receiving Antidepressants
por: Bai, Anthony D., et al.
Publicado: (2022)

Developing an Electroencephalography-Based Model for Predicting Response to Antidepressant Medication
por: Schwartzmann, Benjamin, et al.
Publicado: (2023)

Decreased Prosaposin and Progranulin in the Cingulate Cortex Are Associated with Schizophrenia Pathophysiology
por: He, Yachao, et al.
Publicado: (2022)

Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson’s Disease
por: Antipova, Veronica, et al.
Publicado: (2021)

Antidepressant Use and Risk of Manic Episodes in Children and Adolescents With Unipolar Depression
por: Virtanen, Suvi, et al.
Publicado: (2023)

Magnitude of change with antidepressants and placebo in antidepressant clinical trials using structured, taped and appraised rater interviews (SIGMA-RAPS) compared to trials using traditional semi-structured interviews
por: Khan, Arif, et al.
Publicado: (2014)

Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression
por: Yang, Bangkun, et al.
Publicado: (2016)

α-synuclein−lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients
por: Paslawski, Wojciech, et al.
Publicado: (2019)

Effects of the dopamine depleting agent tetrabenazine in tests evaluating different components of depressive-like behavior in mice: sex-dependent response to antidepressant drugs with SERT and DAT blocker profiles
por: Carratalá-Ros, Carla, et al.
Publicado: (2023)

Association of Recent Fatherhood With Antidepressant Treatment Initiation Among Men in the United Kingdom
por: Smith, Holly Christina, et al.
Publicado: (2023)

Timing of Antidepressant Discontinuation During Pregnancy and Postpartum Psychiatric Outcomes in Denmark and Norway
por: Trinh, Nhung T. H., et al.
Publicado: (2023)

Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease
por: Wallin, Johan, et al.
Publicado: (2021)

Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals
por: Crawford, Andrew A., et al.
Publicado: (2014)

Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats
por: Papp, Mariusz, et al.
Publicado: (2016)

Assessment of a Prediction Model for Antidepressant Treatment Stability Using Supervised Topic Models
por: Hughes, Michael C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a7a528nh47ai66dc9nbe3pbsr1